Zhitong Finance App News, Rongchang Biotech (09995.HK) announced that on November 9, 2026 (after the transaction period), the company signed a license agreement with the licensor Yantai Rongchang Pharmaceutical Co., Ltd. Based on this, the licensor agreed to grant the company an exclusive license to develop, manufacture, commercialize and otherwise use licensed compounds and licensed products worldwide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.